Frank D. Lee, Chief Executive Officer and Director of Pacira BioSciences, Inc., filed a Form 4 on November 17, 2026, disclosing the disposition of common stock and cancellation of a stock option in connection with the consummation of a merger with Viatris Inc.
Key Highlights
- Shares disposed: 660,830.841 shares of common stock were disposed of on November 17, 2026, at a price of $36.50 per share.
- Merger context: The disposal occurred pursuant to the Agreement and Plan of Merger, dated October 8, 2026, among Pacira BioSciences, Inc., Viatris Inc., and Peach Purchaser Sub Inc.
- Post-merger ownership: Following the reported transaction, Lee's direct beneficial ownership of common stock is listed as 0 shares.
- Stock option canceled: A stock option to purchase 692,512 shares of common stock, with an exercise price of $32.07 and expiration date of January 3, 2034, was disposed of on November 17, 2026, with 0 derivative securities remaining.
- RSUs included: According to the filing, the disposed share total included restricted stock unit awards, each of which was canceled and converted into the right to receive $36.50 per underlying share in cash, subject to applicable tax withholdings.
- ESPP shares included: The total also included 1,022.077 shares acquired under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan in June 2026.
Pacira BioSciences CEO's Holdings Extinguished at Viatris Merger Effective Time
According to the filing, Frank D. Lee, serving as both Chief Executive Officer and Director of Pacira BioSciences, Inc. (NASDAQ:PCRX), reported the disposition of 660,830.841 shares of common stock on November 17, 2026, at the offer price of $36.50 per share. The filing states that the disposal occurred because, at the effective time of the merger, each share of Pacira BioSciences common stock "was converted into the right to receive the Offer Price" of $36.50 per share, net of applicable withholding taxes and without interest.
The filing describes the transaction as resulting from a cash tender offer by Peach Purchaser Sub Inc., a subsidiary of Viatris Inc., which consummated the offer to purchase all outstanding shares of Pacira BioSciences common stock. Following the tender offer, Peach Purchaser Sub Inc. merged with and into Pacira BioSciences, with Pacira continuing as the surviving corporation and "a wholly owned subsidiary of Viatris," according to the filing.
In addition to common stock, the filing discloses that a stock option covering 692,512 shares, carrying an exercise price of $32.07 per share, was also disposed of on November 17, 2026. The filing states that, pursuant to the Merger Agreement, each option outstanding as of immediately prior to the effective time was canceled and converted into the right to receive cash equal to the excess of the offer price over the exercise price per share, multiplied by the number of shares subject to the option, subject to applicable tax withholdings. The filing further notes that any option with a per-share exercise price greater than or equal to the offer price was canceled with no consideration payable.
What Was Disclosed
Frank D. Lee, CEO and Director of Pacira BioSciences, reported the full disposition of 660,830.841 shares of common stock and the cancellation of a 692,512-share stock option on November 17, 2026, at the effective time of the company's merger with Viatris Inc., leaving zero shares directly owned.




Please wait processing your request...